Literature DB >> 21129982

A systematic protocol for the characterization of Hsp90 modulators.

Robert L Matts1, Gary E L Brandt, Yuanming Lu, Anshuman Dixit, Mehdi Mollapour, Suiquan Wang, Alison C Donnelly, Leonard Neckers, Gennady Verkhivker, Brian S J Blagg.   

Abstract

Several Hsp90 modulators have been identified including the N-terminal ligand geldanamycin (GDA), the C-terminal ligand novobiocin (NB), and the co-chaperone disruptor celastrol. Other Hsp90 modulators elicit a mechanism of action that remains unknown. For example, the natural product gedunin and the synthetic anti-spermatogenic agent H2-gamendazole, recently identified Hsp90 modulators, manifest biological activity through undefined mechanisms. Herein, we report a series of biochemical techniques used to classify such modulators into identifiable categories. Such studies provided evidence that gedunin and H2-gamendazole both modulate Hsp90 via a mechanism similar to celastrol, and unlike NB or GDA.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129982      PMCID: PMC4618652          DOI: 10.1016/j.bmc.2010.10.029

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  48 in total

Review 1.  Structure and mechanism of the Hsp90 molecular chaperone machinery.

Authors:  Laurence H Pearl; Chrisostomos Prodromou
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

Review 2.  Emerging Hsp90 inhibitors: from discovery to clinic.

Authors:  G Chiosis; A Rodina; K Moulick
Journal:  Anticancer Agents Med Chem       Date:  2006-01       Impact factor: 2.505

3.  A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity.

Authors:  Sabah Ansar; Joseph A Burlison; M Kyle Hadden; Xiao Ming Yu; Kelly E Desino; Jennifer Bean; Len Neckers; Ken L Audus; Mary L Michaelis; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

4.  Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.

Authors:  Sridhar Sreeramulu; Santosh Lakshmi Gande; Michael Göbel; Harald Schwalbe
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

5.  Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.

Authors:  Bo-Geon Yun; Wenjun Huang; Natalie Leach; Steven D Hartson; Robert L Matts
Journal:  Biochemistry       Date:  2004-06-29       Impact factor: 3.162

6.  A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone.

Authors:  Shin-ichi Yamada; Toshio Ono; Akio Mizuno; Takayuki K Nemoto
Journal:  Eur J Biochem       Date:  2003-01

Review 7.  Natural product inhibitors of Hsp90: potential leads for drug discovery.

Authors:  M W Amolins; B S J Blagg
Journal:  Mini Rev Med Chem       Date:  2009-02       Impact factor: 3.862

8.  Mechanism of dimer formation of the 90-kDa heat-shock protein.

Authors:  T Nemoto; Y Ohara-Nemoto; M Ota; T Takagi; K Yokoyama
Journal:  Eur J Biochem       Date:  1995-10-01

Review 9.  Hsp90: a novel target for the disruption of multiple signaling cascades.

Authors:  Stephanie C Bishop; Joseph A Burlison; Brian S J Blagg
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

Review 10.  The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review.

Authors:  P Csermely; T Schnaider; C Soti; Z Prohászka; G Nardai
Journal:  Pharmacol Ther       Date:  1998-08       Impact factor: 12.310

View more
  40 in total

1.  Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Authors:  Hardik J Patel; Pallav D Patel; Stefan O Ochiana; Pengrong Yan; Weilin Sun; Maulik R Patel; Smit K Shah; Elisa Tramentozzi; James Brooks; Alexander Bolaender; Liza Shrestha; Ralph Stephani; Paola Finotti; Cynthia Leifer; Zihai Li; Daniel T Gewirth; Tony Taldone; Gabriela Chiosis
Journal:  J Med Chem       Date:  2015-04-22       Impact factor: 7.446

2.  Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

Review 3.  Adapting to stress - chaperome networks in cancer.

Authors:  Suhasini Joshi; Tai Wang; Thaís L S Araujo; Sahil Sharma; Jeffrey L Brodsky; Gabriela Chiosis
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

Review 4.  Selective targeting of the stress chaperome as a therapeutic strategy.

Authors:  Tony Taldone; Stefan O Ochiana; Pallav D Patel; Gabriela Chiosis
Journal:  Trends Pharmacol Sci       Date:  2014-09-25       Impact factor: 14.819

5.  Gambogic acid, a natural product inhibitor of Hsp90.

Authors:  Jason Davenport; Jacob R Manjarrez; Laura Peterson; Brian Krumm; Brian S J Blagg; Robert L Matts
Journal:  J Nat Prod       Date:  2011-04-12       Impact factor: 4.050

6.  Proteasome-Dependent Regulation of Distinct Metabolic States During Long-Term Culture of Human iPSC-Derived Cardiomyocytes.

Authors:  Antje Ebert; Amit U Joshi; Sandra Andorf; Yuanyuan Dai; Shrivatsan Sampathkumar; Haodong Chen; Yingxin Li; Priyanka Garg; Karl Toischer; Gerd Hasenfuss; Daria Mochly-Rosen; Joseph C Wu
Journal:  Circ Res       Date:  2019-05-20       Impact factor: 17.367

Review 7.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

Review 8.  The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention.

Authors:  Abdelmagid M Elmatboly; Ahmed M Sherif; Dalia A Deeb; Amira Benmelouka; May N Bin-Jumah; Lotfi Aleya; Mohamed M Abdel-Daim
Journal:  Environ Sci Pollut Res Int       Date:  2020-02-19       Impact factor: 4.223

9.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.

Authors:  Suman Ghosh; Yang Liu; Gaurav Garg; Mercy Anyika; Nolan T McPherson; Jiacheng Ma; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

10.  Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β.

Authors:  Kendrick H Yim; Thomas L Prince; Shiwei Qu; Fang Bai; Patricia A Jennings; José N Onuchic; Emmanuel A Theodorakis; Leonard Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.